Price (delayed)
$39.1
Market cap
$2.27B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.18
Enterprise value
$2.08B
Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The
There are no recent dividends present for MRTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.